CAJ | 학술논문

目的：观察肾康注射液联合羟苯磺酸钙治疗慢性肾功能衰竭的疗效，并探讨其对肾脏的保护机制。方法选取125例慢性肾功能衰竭患者，随机分为两组，治疗组65例，对照组60例。治疗组按K/DOQI标准分为治疗A组（K/DOQI第3期）及治疗B组（K/DOQI第4期）。两组均给予口服羟苯磺酸钙及常规综合治疗，治疗组在此基础上加用肾康注射液。观察两组患者治疗前后及停药4周后治疗A组和B组血清肌酐（Scr）、血尿素氮（BUN）、血尿酸（UA）、内生肌酐清除率（Ccr）、血清胱抑素C（CysC）、血红蛋白（Hb）等各指标变化情况。结果与对照组相比，治疗组在降低Scr，BUN，UA，CysC各指标水平，以及提高Ccr和Hb等方面明显优于对照组（ P<0.05）；治疗后，上述各指标改善状况A组优于B组。结论肾康注射液联合羟苯磺酸钙可改善慢性肾功能衰竭患者的肾脏功能，且早期患者疗效明显。其作用机制可能是肾康注射液抑制了肾内转化生长因子β（TGF-β）的表达，延缓了肾小球硬化的发生。
목적：관찰신강주사액연합간분광산개치료만성신공능쇠갈적료효，병탐토기대신장적보호궤제。방법선취125례만성신공능쇠갈환자，수궤분위량조，치료조65례，대조조60례。치료조안K/DOQI표준분위치료A조（K/DOQI제3기）급치료B조（K/DOQI제4기）。량조균급여구복간분광산개급상규종합치료，치료조재차기출상가용신강주사액。관찰량조환자치료전후급정약4주후치료A조화B조혈청기항（Scr）、혈뇨소담（BUN）、혈뇨산（UA）、내생기항청제솔（Ccr）、혈청광억소C（CysC）、혈홍단백（Hb）등각지표변화정황。결과여대조조상비，치료조재강저Scr，BUN，UA，CysC각지표수평，이급제고Ccr화Hb등방면명현우우대조조（ P<0.05）；치료후，상술각지표개선상황A조우우B조。결론신강주사액연합간분광산개가개선만성신공능쇠갈환자적신장공능，차조기환자료효명현。기작용궤제가능시신강주사액억제료신내전화생장인자β（TGF-β）적표체，연완료신소구경화적발생。
Objective To observe the effect of Shenkang Iinjection combined with calcium dobesilate in treating chronic renal failure (CRF) and to investigate its protective mechanism to kidney. Methods 125 patients with CRF were randomly divided into the treat-ment group(65 cases) and the control group(60 cases);the treatment group was subdivided into the group A(stage Ⅲ) and B(stageⅣ) according to the Kidney Disease Outcome Quality Initiative(K/DOQI) standard. The two groups were treated with orally calcium dobesilate and the routine comprehensive therapy,on this basis,the treatment group was added with Shenkang Injection. The change of indexes of serum Scr,BUN,UA,Ccr,CysC and Hb before treatment,after treatment and at 4 weeks after drug withdrawal were observed and compared between the two groups. Results The treatment group was significantly superior to the control group in reducing the lev-els of serum Scr,BUN,UA and CysC and increasing the levels of Ccr and Hb( P < 0. 05);the improvement of above indexes after treatment in the group A was superior to that in the group B. Conclusion Shenkang Injection combined with calcium dobesilate can improve the renal function in the patients with CRF and has significant effect in early stage,its mechanism may be that Shenkang In-jection inhibits the expression of renal transforming growth factor-β(TGF-β )and retards the occurrence of glomerular sclerosis.